CN101600726B - 用于治疗病毒感染的核苷类似物 - Google Patents

用于治疗病毒感染的核苷类似物 Download PDF

Info

Publication number
CN101600726B
CN101600726B CN2008800031040A CN200880003104A CN101600726B CN 101600726 B CN101600726 B CN 101600726B CN 2008800031040 A CN2008800031040 A CN 2008800031040A CN 200880003104 A CN200880003104 A CN 200880003104A CN 101600726 B CN101600726 B CN 101600726B
Authority
CN
China
Prior art keywords
virus
compound
ethynyl
compounds
pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008800031040A
Other languages
English (en)
Chinese (zh)
Other versions
CN101600726A (zh
Inventor
尹正
J·杜赖斯瓦米
Y·L·陈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39462074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101600726(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN101600726A publication Critical patent/CN101600726A/zh
Application granted granted Critical
Publication of CN101600726B publication Critical patent/CN101600726B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN2008800031040A 2007-02-09 2008-02-07 用于治疗病毒感染的核苷类似物 Expired - Fee Related CN101600726B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07102027 2007-02-09
EP07102027.5 2007-02-09
EP08150003 2008-01-02
EP08150003.5 2008-01-02
PCT/EP2008/051527 WO2008095993A1 (en) 2007-02-09 2008-02-07 Novel nucleoside analogs for treatment of viral infections

Publications (2)

Publication Number Publication Date
CN101600726A CN101600726A (zh) 2009-12-09
CN101600726B true CN101600726B (zh) 2013-03-27

Family

ID=39462074

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008800031040A Expired - Fee Related CN101600726B (zh) 2007-02-09 2008-02-07 用于治疗病毒感染的核苷类似物

Country Status (18)

Country Link
US (1) US8278282B2 (enExample)
EP (1) EP2132216B1 (enExample)
JP (1) JP2010518047A (enExample)
KR (1) KR20090109102A (enExample)
CN (1) CN101600726B (enExample)
AR (1) AR065249A1 (enExample)
AT (1) ATE533774T1 (enExample)
AU (1) AU2008212752A1 (enExample)
BR (1) BRPI0807222A2 (enExample)
CA (1) CA2675462A1 (enExample)
CL (1) CL2008000409A1 (enExample)
EA (1) EA200901080A1 (enExample)
ES (1) ES2381093T3 (enExample)
MX (1) MX2009008495A (enExample)
PE (1) PE20090070A1 (enExample)
PT (1) PT2132216E (enExample)
TW (1) TW200838550A (enExample)
WO (1) WO2008095993A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010015643A1 (en) * 2008-08-06 2010-02-11 Novartis Ag New antiviral modified nucleosides
CN102526087B (zh) * 2010-12-30 2014-09-03 南开大学 核苷类化合物在制备治疗肠病毒71(ev71)感染疾病药物的应用
CN105669783B (zh) * 2014-12-03 2019-11-12 广东东阳光药业有限公司 一种制备呋喃糖的方法
BR112018002399A2 (pt) 2015-08-06 2018-09-25 Chimerix, Inc. nucleosídeos de pirrolopirimidina e análogos dos mesmos, úteis como agentes antivirais
WO2017053216A2 (en) 2015-09-23 2017-03-30 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof
US11192914B2 (en) * 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
TW201815821A (zh) * 2016-07-18 2018-05-01 美商再生元醫藥公司 抗茲卡病毒抗體及使用方法
EP3497111A2 (en) * 2016-08-12 2019-06-19 Janssen BioPharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP3684771B1 (en) 2017-09-21 2024-11-27 Chimerix, Inc. Morphic forms of 4-amino-7-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7h-pyrrolo(2,3-d)pyrimidine-5-carboxamide and uses thereof
WO2020219447A1 (en) 2019-04-23 2020-10-29 Elementis Specialties, Inc. Slurry compositions containing mixed branched alkyl organoclay compositions
AU2022422062B2 (en) * 2021-12-22 2025-08-14 Cj Cheiljedang Corporation Antiviral composition comprising nucleoside analogues derived from nucleic acid and pharmaceutically acceptable salt thereof
WO2024012568A1 (en) * 2022-07-15 2024-01-18 Sunshine Lake Pharma Co., Ltd. A key intermediate for preparing glucopyranosyl derivatives and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068244A1 (en) * 2002-02-13 2003-08-21 Merck & Co., Inc. Methods of inhibiting orthopoxvirus replication with nucleoside compounds
WO2003093290A2 (en) * 2002-05-06 2003-11-13 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection
WO2004028481A2 (en) * 2002-09-30 2004-04-08 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0400726A3 (en) * 2001-01-22 2007-05-29 Merck & Co Inc Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US7005448B2 (en) 2001-12-14 2006-02-28 Alcon, Inc. Aminoalkyl-benzofuran-5-ol compounds for the treatment of glaucoma
US20040259934A1 (en) 2003-05-01 2004-12-23 Olsen David B. Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
US7157434B2 (en) * 2003-10-27 2007-01-02 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068244A1 (en) * 2002-02-13 2003-08-21 Merck & Co., Inc. Methods of inhibiting orthopoxvirus replication with nucleoside compounds
WO2003093290A2 (en) * 2002-05-06 2003-11-13 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection
WO2004028481A2 (en) * 2002-09-30 2004-04-08 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection

Also Published As

Publication number Publication date
KR20090109102A (ko) 2009-10-19
JP2010518047A (ja) 2010-05-27
EP2132216A1 (en) 2009-12-16
EP2132216B1 (en) 2011-11-16
ATE533774T1 (de) 2011-12-15
CA2675462A1 (en) 2008-08-14
US20100227833A1 (en) 2010-09-09
EA200901080A1 (ru) 2010-02-26
TW200838550A (en) 2008-10-01
BRPI0807222A2 (pt) 2014-04-29
AU2008212752A1 (en) 2008-08-14
ES2381093T3 (es) 2012-05-23
CL2008000409A1 (es) 2008-08-29
AR065249A1 (es) 2009-05-27
MX2009008495A (es) 2009-08-20
CN101600726A (zh) 2009-12-09
WO2008095993A1 (en) 2008-08-14
PT2132216E (pt) 2012-02-20
PE20090070A1 (es) 2009-03-19
US8278282B2 (en) 2012-10-02

Similar Documents

Publication Publication Date Title
CN101600726B (zh) 用于治疗病毒感染的核苷类似物
US20100144655A1 (en) Organic compounds
WO2010015637A1 (en) New antiviral modified nucleosides
CN104163841B (zh) 用于治疗黄病毒感染的修饰的2’和3’-核苷前药
KR101218882B1 (ko) 스피로피롤리딘, 및 ｈｃｖ 및 ｈｉｖ 감염에 대한 그의 용도
EP2604620B2 (en) Modified fluorinated nucleoside analogues
KR20060084845A (ko) Ｃ형 간염을 포함하는 플라비비리다에를 치료하기 위한퓨린 뉴클레오시드 유사체
KR20080111123A (ko) Ｈｃｖ/ｈｉｖ 억제제 및 이들의 용도
KR20120004521A (ko) 유기 화합물 및 그의 용도
US20160289259A1 (en) 2'-Branched Nucleosides for Treatment of Viral Infections
AU2012204097B2 (en) Novel nucleoside analogs for treatment of viral infections
CN1761677A (zh) 用于治疗黄病毒感染的修饰的2'和3'－核苷前药
HK1189235A (en) Modified 2' and 3' -nucleoside prodrugs for treating flaviviridae infections
HK1189234A (en) Modified 2' and 3'-nucleoside prodrugs for treating flaviridae infections
HK1187349B (en) Modified fluorinated nucleoside analogues

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130327

Termination date: 20140207